1stOncology™: Cancer Intelligence Service – Page 13213 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

CNS Pharmaceuticals Announces Full Exercise of Over-Allotment Option

On November 21, 2019 CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, reported the closing of the issuance of an additional 318,750 shares of its common stock pursuant to the exercise in full of the underwriters’ over-allotment option in connection with its initial public offering (the "IPO") (Press release, CNS Pharmaceuticals, NOV 21, 2019, View Source [SID1234551596]). The additional shares were sold at the IPO price of $4.00 per share, before underwriting discounts and commissions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The gross proceeds from the sale of the additional shares, before deducting underwriting discounts and commissions, was $1.3 million, bringing the total gross proceeds from the IPO to $9.8 million. The Company’s shares of common stock trade on the NASDAQ Capital Market under the ticker symbol "CNSP."

The Benchmark Company, LLC acted as sole Book Running Manager for the offering.

A registration statement on Form S-1 (File No. 333-232443) relating to the shares was filed with the Securities and Exchange Commission ("SEC") and became effective on November 7, 2019. The offering was made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained from The Benchmark Company, LLC, Attn: Prospectus Department, 150 E 58th Street, 17th floor, New York, NY 10155, 212-312-6700, Email: [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Berubicin
Berubicin is an anthracycline, a class of drugs among the most powerful chemotherapy drugs and effective against more types of cancer than any other class of chemotherapeutic agents. Anthracyclines are designed to damage the DNA of targeted cancer cells by interfering with the action of the topoisomerase II, a critical enzyme enabling cell proliferation. Berubicin was developed at the MD Anderson Cancer Center (MDACC), the world’s largest cancer research facility. Berubicin appeared to demonstrate one Durable Complete Response in a Phase I human clinical trial conducted by a prior developer.

BRUKINSA™ (zanubrutinib) Approved for the Treatment of Mantle Cell Lymphoma, Available from Onco360

On November 21, 2019 Onco360, the nation’s largest independent Oncology Pharmacy, reported that it has been selected by BeiGene to be a specialty pharmacy network partner for BRUKINSA (zanubrutinib), a new oral treatment for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy (Press release, Onco360, NOV 21, 2019, View Source [SID1234551594]).

"The approval of BRUKINSA as a second-line therapy option for patients with relapsed and refractory MCL is an important advancement in fighting this devastating disease"

"The approval of BRUKINSA as a second-line therapy option for patients with relapsed and refractory MCL is an important advancement in fighting this devastating disease," said Paul Jardina, President and CEO, Onco360. "As a specialty pharmacy dedicated to serving people with cancer, Onco360 is pleased to be one of a few pharmacies bringing this new innovative treatment to MCL patients."

According to the American Cancer Society, Mantle cell lymphoma is a type of non-Hodgkin’s lymphoma representing 3-10% of all non-Hodgkin’s lymphomas in the United States. By the time it is diagnosed, mantle cell lymphoma has usually spread to the lymph nodes, bone marrow and other organs. In relapsed lymphoma, the disease reappears or grows again after a period of remission, while in refractory lymphoma, the disease does not respond to treatment or responds only briefly.

BRUKINSA is manufactured by BeiGene, a global, commercial-stage, research-based biotechnology company, and was approved by the U.S. Food and Drug Administration (FDA) to treat adult patients with MCL on November 14, 2019. The FDA’s approval of BRUKINSA is based on efficacy results from two single-arm clinical trials, with independent review committee (IRC)-assessed ORR per 2014 Lugano Classification as the primary endpoint. Across both trials, BRUKINSA achieved an ORR, which is the sum of complete responses and partial responses, of 84%. For full prescribing information, visit BRUKINSA.com.

BostonGene to Present Multiple Abstracts at the 2019 American Society of Hematology (ASH) Annual Meeting

On November 21, 2019 BostonGene Corporation (BostonGene), a Boston-based biomedical software company, reported that as a result of its collaborations, multiple abstracts have been accepted for presentation at the 61st American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition to be held December 7-10, 2019 in Orlando, Florida (Press release, BostonGene, NOV 21, 2019, View Source [SID1234551593]). In addition, BostonGene will exhibit at booth #152 in Hall B.

The presentations will provide results demonstrating the role of the tumor microenvironment in cancer classification and treatment outcomes. By combing whole exome and transcriptome sequencing analysis, the significance of stromal and immune compartments of microenvironment in therapeutically relevant categories of Mantle Cell Lymphomas and Diffuse Large B-Cell Lymphoma (DLBCL) is identified.

POSTER PRESENTATION

Sunday, December 8, 2019: 6:00 PM – 8:00 PM in Hall B, Level 2

Title: Tumor Microenvironment Molecular Signatures That Define Therapeutic Resistance in Mantle Cell Lymphoma (Abstract 2762)
Presenter: Krystle Nomie, The University of Texas MD Anderson Cancer Center
Session: 621. Lymphoma—Genetic/Epigenetic Biology: Poster II
ORAL PRESENTATION

Monday, December 9, 2019: 10:45 AM in Tangerine 2 (WF2), Level 2

Title: Microenvironmental Signatures Reveal Biological Subtypes of Diffuse Large B-Cell Lymphoma (DLBCL) Distinct from Tumor Cell Molecular Profiling (Abstract 656)
Presenter: Leandro Cerchietti, MD, Weill Cornell Medicine
Session: 622. Lymphoma Biology—Non-Genetic Studies: Tumor Microenvironment
Additional information on abstracts for the ASH (Free ASH Whitepaper) Annual Meeting can be found here: View Source

"We are excited to share our success as a strategic collaborator with two of the leading cancer centers in the world at this year’s ASH (Free ASH Whitepaper) event. We look forward to showcasing our innovative platform that will ultimately impact and improve cancer patients’ chances for survival," said Andrew Feinberg, President & CEO at BostonGene.

Personalis, Inc. to Present at NeoAg Summit US 2019

On November 21, 2019 Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, reported that the company will present at the NeoAg Summit US 2019 in Boston on November 21st at 9:15 AM EST (Press release, Personalis, NOV 21, 2019, View Source [SID1234551591]).

The presentation, entitled "ImmunoID NeXT: A Comprehensive Platform for Improving Neoantigen Prediction, Tumor Escape Mechanism Reporting, TME Assessment, and Tumor Heterogeneity Profiling for Immuno-Oncology," will provide an overview of Personalis’ newly-launched cancer immunogenomics platform, specifically highlighting innovative machine learning-based methods for the comprehensive identification of neoantigens and the detection of emerging and novel biomarkers of response and resistance to immunotherapy.

ImmunoID NeXT is the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample. ImmunoID NeXT can be used to investigate the key tumor- and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one and maximizing the biological information that can be generated from a precious tumor specimen.

The presentation will be delivered by Sean M. Boyle, PhD, Sr. Director, Bioinformatics Applications for Personalis.

Personalis will also be exhibiting during the conference (Exhibit #9). Representatives will be available to answer questions about the company’s cancer immunogenomics capabilities.

Clover Biopharmaceuticals Doses First Patient in Phase I Study of SCB-313 in Australia for Malignant Pleural Effusions (MPE)

On November 21, 2019 Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, reported that the first patient was dosed in a Phase I trial of SCB-313, an investigational fully-human TRAIL-Trimer fusion protein, in Australia for the treatment of cancer patients with malignant pleural effusions (MPE) (Press release, Clover Biopharmaceuticals, NOV 21, 2019, View Source [SID1234551590]). There are now five clinical studies evaluating SCB-313 open to recruiting patients in China and Australia across three oncology indications (malignant ascites, peritoneal carcinomatosis, and malignant pleural effusions).

"MPE has historically posed significant challenges for both patients and clinicians, and it remains a high unmet medical need for many cancer patients worldwide," said Dr. Y. C. Gary Lee, Director of Pleural Medicine at Sir Charles Gairdner Hospital, Perth, Australia.

The Phase I, open-label, dose escalation trial in Australia is designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of intrapleural administered SCB-313 for the treatment of MPE. Several sites in Australia, including Dr. Lee’s unit, are participating in this study.

"We are excited to work with these world-class investigators and sites participating in this study," said Dr. Min Dong, Executive Vice President, Global Clinical Development at Clover. "Now that Clover has successfully initiated clinical studies evaluating SCB-313 in multiple countries, we hope to bring this novel and potentially first-in-class therapy to patients worldwide."

"TRAIL has long been considered a tantalizing target for cancer therapy because it can induce apoptosis in a tumor-specific manner across many different tumor types. SCB-313, which utilizes our proprietary Trimer-Tag© technology, is able to potently and uniquely target this trimerization-dependent pathway," said Dr. Peng Liang, co-founder, Chairman and President of Clover. "We believe that SCB-313 has the potential to be a best-in-class TRAIL-based therapy based on our R&D results to date, and in the months ahead, we look forward to initiating multiple new clinical studies for the treatment of intracavitary cancers."